Paper7720510
Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes.
Idowu OR and 3 others. Drug Metab Dispos, 1995. Cited by 29 papers, by iCite.
Cite this record
ConductScience Library. Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes. Papers, record 7720510. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7720510
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminoquinolines | Major topic |
| Antimalarials | Major topic |
| Microsomes, Liver | Major topic |
| Animals | |
| Chromatography, Gas | |
| Chromatography, High Pressure Liquid | |
| In Vitro Techniques | |
| Male | |
| Mass Spectrometry | |
| Oxidation-Reduction | |
| Primaquine | |
| Rats | |
| Rats, Sprague-Dawley | |
| Spectrophotometry, Ultraviolet |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39339162 | Pharmacokinetic Models of Tafenoquine: Insights for Optimal Malaria Treatment Strategies. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39339162 | PubMed |
| 38640243 | Liver-targeted polymeric prodrugs delivered subcutaneously improve tafenoquine therapeutic window for malaria radical cure. | Sci Adv | 2024 | https://conductscience.org/library/papers/38640243 | PubMed |
| 32073254 | Tafenoquine: A Step toward Malaria Elimination. | Biochemistry | 2020 | https://conductscience.org/library/papers/32073254 | PubMed |
| 30881061 | Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data. | Infect Drug Resist | 2019 | https://conductscience.org/library/papers/30881061 | PubMed |
| 30442143 | Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study. | Malar J | 2018 | https://conductscience.org/library/papers/30442143 | PubMed |
| 25870069 | Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/25870069 | PubMed |
| 23782898 | The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. | Malar J | 2013 | https://conductscience.org/library/papers/23782898 | PubMed |
| 22042867 | Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. | Proc Natl Acad Sci U S A | 2011 | https://conductscience.org/library/papers/22042867 | PubMed |
| 11432537 | Pharmacokinetic interactions of antimalarial agents. | Clin Pharmacokinet | 2001 | https://conductscience.org/library/papers/11432537 | PubMed |
| 10049273 | 8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. | Antimicrob Agents Chemother | 1999 | https://conductscience.org/library/papers/10049273 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7720510
GET https://conductscience.org/api/papers/v1/7720510/authors